Adverse event profile
| Placebo(n = 222) | Salmeterol(n = 216) | |
|---|---|---|
| *Events reported by >5% in either treatment group. | ||
| †No event related to study medication. | ||
| ‡Only includes patients withdrawn with adverse events which began after treatment was started. | ||
| Adverse events, n (%) | 161 (51) | 143 (45) |
| Most common events, n (%)* | ||
| Upper respiratory tract infection | 24 (8) | 18 (6) |
| Breathing problems | 23 (7) | 18 (6) |
| Cough | 15 (5) | 15 (5) |
| Adverse events considered drug related, n (%) | 14 (4%) | 11 (3%) |
| Serious adverse events, n (%) | 37 (12%) | 32 (10%) |
| Deaths† | 5 (2%) | 6 (2%) |
| Adverse events leading to discontinuation‡ | 19 (6%) | 14 (4%) |